Literature DB >> 20118392

Use of drug-eluting stents in patients with coronary artery disease and renal insufficiency.

Ayman A El-Menyar1, Jassim Al Suwaidi, David R Holmes.   

Abstract

Renal insufficiency (RI) has been shown to be associated with increased major adverse cardiovascular events after percutaneous coronary intervention. We reviewed the impact of RI on the pathogenesis of coronary artery disease and outcomes after percutaneous coronary intervention in the form of drug-eluting stent (DES) implantation in these high-risk patients. We searched the English-language literature indexed in MEDLINE, Scopus, and EBSCO Host research databases from 1990 through January 2009, using as search terms coronary revascularization, drug-eluting stent, and renal insufficiency. Studies that assessed DES implantation in patients with various degrees of RI were selected for review. Most of the available data were extracted from observational studies, and data from randomized trials formed the basis of a post hoc analysis. The outcomes after coronary revascularization were less favorable in patients with RI than in those with normal renal function. In patients with RI, DES implantation yielded better outcomes than did use of bare-metal stents. Randomized trials are needed to define optimal treatment of these high-risk patients with coronary artery disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20118392      PMCID: PMC2813825          DOI: 10.4065/mcp.2009.0314

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  66 in total

1.  Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables.

Authors:  George Dangas; Ioannis Iakovou; Eugenia Nikolsky; Eve D Aymong; Gary S Mintz; Nicholas N Kipshidze; Alexandra J Lansky; Issam Moussa; Gregg W Stone; Jeffrey W Moses; Martin B Leon; Roxana Mehran
Journal:  Am J Cardiol       Date:  2005-01-01       Impact factor: 2.778

2.  Rates of stent thrombosis in bare-metal versus drug-eluting stents (from a large Australian multicenter registry).

Authors:  Bryan P Yan; Stephen J Duffy; David J Clark; Jeffery Lefkovits; Roderic Warren; Ronen Gurvitch; Robert Lew; Martin Sebastian; Angela Brennan; Nick Andrianopoulos; Christopher M Reid; Andrew E Ajani
Journal:  Am J Cardiol       Date:  2008-04-09       Impact factor: 2.778

3.  Treatment of coronary artery disease in dialysis patients with sirolimus-eluting stents: 1-year clinical follow-up of a consecutive series of cases.

Authors:  Joost Daemen; Pedro Lemos; Jiro Aoki; Chourmouzios Arampatzis; Angela Hoye; Eugene McFadden; Patrick Serruys
Journal:  J Invasive Cardiol       Date:  2004-12       Impact factor: 2.022

4.  Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial).

Authors:  Derek P Chew; A Michael Lincoff; Hitinder Gurm; Katherine Wolski; David J Cohen; Tim Henry; Frederick Feit; Eric J Topol
Journal:  Am J Cardiol       Date:  2005-03-01       Impact factor: 2.778

5.  Hemostatic disorder of uremia: the platelet defect, main determinant of the prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis.

Authors:  D Mezzano; R Tagle; O Panes; M Pérez; P Downey; B Muñoz; E Aranda; P Barja; S Thambo; F González; S Mezzano; J Pereira
Journal:  Thromb Haemost       Date:  1996-09       Impact factor: 5.249

6.  Impact of mild or moderate chronic kidney disease on the frequency of restenosis: results from the PRESTO trial.

Authors:  Patricia J M Best; Peter B Berger; Barry R Davis; Cindy L Grines; H Mehrdad Sadeghi; Brent A Williams; James T Willerson; Jeffrey R Granett; David R Holmes
Journal:  J Am Coll Cardiol       Date:  2004-11-02       Impact factor: 24.094

7.  Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial.

Authors:  Adnan Kastrati; Julinda Mehilli; Nicolas von Beckerath; Alban Dibra; Jörg Hausleiter; Jürgen Pache; Helmut Schühlen; Claus Schmitt; Josef Dirschinger; Albert Schömig
Journal:  JAMA       Date:  2005-01-12       Impact factor: 56.272

8.  Impact of baseline renal function on mortality after percutaneous coronary intervention with sirolimus-eluting stents or bare metal stents.

Authors:  Pedro A Lemos; Chourmouzios A Arampatzis; Angela Hoye; Joost Daemen; Andrew T L Ong; Francesco Saia; Willem J van der Giessen; Eugene P McFadden; Georgios Sianos; Pieter C Smits; Pim de Feyter; Sjoerd H Hofma; Ron T van Domburg; Patrick W Serruys
Journal:  Am J Cardiol       Date:  2005-01-15       Impact factor: 2.778

9.  Cytokine production during hemodialysis: effects of dialytic membrane and complement activation.

Authors:  Y F Lin; D M Chang; M F Shaio; K C Lu; S H Chyr; B L Li; S D Sheih
Journal:  Am J Nephrol       Date:  1996       Impact factor: 3.754

10.  The association between kidney function, coronary artery disease, and clinical outcome in patients undergoing coronary angiography.

Authors:  Ki Young Na; Chi Weon Kim; Young Rim Song; Ho Joon Chin; Dong-Wan Chae
Journal:  J Korean Med Sci       Date:  2009-01-28       Impact factor: 2.153

View more
  5 in total

1.  Long-Term Percutaneous Coronary Intervention Outcomes of Patients with Chronic Kidney Disease in the Era of Second-Generation Drug-Eluting Stents.

Authors:  Wojciech Wańha; Damian Kawecki; Tomasz Roleder; Aleksandra Pluta; Kamil Marcinkiewicz; Beata Morawiec; Janusz Dola; Sylwia Gładysz; Tomasz Pawłowski; Grzegorz Smolka; Andrzej Ochała; Ewa Nowalany-Kozielska; Wojciech Wojakowski
Journal:  Cardiorenal Med       Date:  2016-12-09       Impact factor: 2.041

2.  Dual Antiplatelet Therapy and Clinical Outcomes after Coronary Drug-Eluting Stent Implantation in Patients on Hemodialysis.

Authors:  Yung-Tai Chen; Hung-Ta Chen; Chien-Yi Hsu; Pei-Wen Chao; Shu-Chen Kuo; Shuo-Ming Ou; Chia-Jen Shih
Journal:  Clin J Am Soc Nephrol       Date:  2017-02-07       Impact factor: 8.237

Review 3.  Coronary Revascularization in Patients with CKD Stage 5D: Pragmatic Considerations.

Authors:  Gautam R Shroff; Charles A Herzog
Journal:  J Am Soc Nephrol       Date:  2016-08-04       Impact factor: 10.121

4.  Cardiovascular Outcomes in Patients on Hemodialysis following Drug-Eluting versus Bare-Metal Coronary Stents.

Authors:  Amir F Mohani; Srikanth Penumetsa; Amin Daoulah; Gregory Giugliano; Amir Lotfi
Journal:  Cardiol Res Pract       Date:  2018-05-17       Impact factor: 1.866

5.  Cardiovascular risk factors profile in patients with acute coronary syndrome with particular reference to left ventricular ejection fraction.

Authors:  Sheeren Khaled; Rajaa Matahen
Journal:  Indian Heart J       Date:  2017-05-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.